To study this, various concentrations (1 nM to 10 μM) of Meds433 for treatment of newly diagnosed (Fig. 1A) and resistant CML CD34+ cells (Fig. 1B) were used for 3 days (Flow cytometry graphs of one newly diagnosed patient sample treated with Meds433 are displayed in Fig. 1A right panel). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.